** Shares of drugmaker TG Therapeutics TGTX.O rise 15.7% to $34.82
** Co posts Q4 net product revenue of $107.3 million, beating analysts' average estimate of $99.98 million - data compiled by LSEG
** TGTX's Q4 U.S. net product revenue for relapsing multiple sclerosis drug Briumvi came in at $103.6 million
** Co forecasts 2025 total revenue of about $540 million, compared with estimates of $548.2 million
** TGTX rose 71% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。